Alkermes plc (NASDAQ:ALKS) is a biopharmaceutical company that focuses on developing innovative medicines for central nervous system disorders, including schizophrenia, depression, and addiction. The company operates in a competitive landscape alongside peers like Neurocrine Biosciences, Inc. (NBIX), Alnylam Pharmaceuticals, Inc. (ALNY), BioMarin Pharmaceutical Inc. (BMRN), Incyte Corporation (INCY), and Nektar Therapeutics (NKTR).

Alkermes showcases a robust Return on Invested Capital (ROIC) of 22.09%, significantly surpassing its Weighted Average Cost of Capital (WACC) of 6.68%. This results in a ROIC to WACC ratio of 3.31, indicating that Alkermes is effectively generating returns well above its cost of capital. This efficiency in capital utilization sets Alkermes apart from its peers.

In comparison, Neurocrine Biosciences has a ROIC of 12.66% and a WACC of 5.75%, leading to a ROIC to WACC ratio of 2.20. While this is a positive indicator of capital efficiency, it still falls short of Alkermes' performance. Neurocrine's ability to generate returns above its cost of capital is commendable, yet Alkermes remains the leader.

Alnylam Pharmaceuticals, with a negative ROIC of -4.21% against a WACC of 6.10%, results in a ROIC to WACC ratio of -0.69. This negative ratio suggests that Alnylam is struggling to generate returns that exceed its cost of capital, highlighting challenges in its capital efficiency.

BioMarin Pharmaceutical and Incyte Corporation also face challenges, with ROIC to WACC ratios of 1.04 and 0.02, respectively. These figures indicate that their returns are barely above or even below their cost of capital. Nektar Therapeutics, with a ROIC of -51.91% and a WACC of 12.80%, has a ROIC to WACC ratio of -4.06, further emphasizing its difficulties in capital utilization.